|
1
|
DeSantis CE, Ma J, Goding Sauer A, Newman
LA and Jemal A: Breast cancer statistics, 2017, racial disparity in
mortality by state. CA Cancer J Clin. 67:439–448. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miller KD, Nogueira L, Mariotto AB,
Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel
RL: Cancer treatment and survivorship statistics, 2019. CA Cancer J
Clin. 69:363–385. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Khosravi-Shahi P, Cabezon-Gutierrez L and
Custodio-Cabello S: Metastatic triple negative breast cancer:
Optimizing treatment options, new and emerging targeted therapies.
Asia Pac J Clin Oncol. 14:32–39. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pankov R and Yamada KM: Fibronectin at a
glance. J Cell Sci. 115:3861–3863. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Albrecht M, Renneberg H, Wennemuth G,
Möschler O, Janssen M, Aumüller G and Konrad L: Fibronectin in
human prostatic cells in vivo and in vitro: Expression,
distribution, and pathological significance. Histochem Cell Biol.
112:51–61. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fernandez-Garcia B, Eiro N, Marin L,
González-Reyes S, González LO, Lamelas ML and Vizoso FJ: Expression
and prognostic significance of fibronectin and matrix
metalloproteases in breast cancer metastasis. Histopathology.
64:512–522. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Anderegg U, Breitschwerdt K, Kohler MJ,
Sticherling M, Haustein UF, Simon JC and Saalbach A: MEL4B3, a
novel mRNA is induced in skin tumors and regulated by TGF-beta and
pro-inflammatory cytokines. Exp Dermatol. 14:709–718. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Das DK, Naidoo M, Ilboudo A, Park JY, Ali
T, Krampis K, Robinson BD, Osborne JR and Ogunwobi OO: miR-1207-3p
regulates the androgen receptor in prostate cancer via
FNDC1/fibronectin. Exp Cell Res. 348:190–200. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Valster A, Tran NL, Nakada M, Berens ME,
Chan AY and Symons M: Cell migration and invasion assays. Methods.
37:208–215. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pijuan J, Barcelo C, Moreno DF, Maiques O,
Sisó P, Marti RM, Macià A and Panosa A: In vitro cell migration,
invasion, and adhesion assays: From cell imaging to data analysis.
Front Cell Dev Biol. 7:1072019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu YP, Chen WD, Li WN and Zhang M:
Overexpression of FNDC1 relates to poor prognosis and its knockdown
impairs cell invasion and migration in gastric cancer. Technol
Cancer Res Treat. Jan 1–2019.(Epub ahead of print). doi:
10.1177/1533033819869928. View Article : Google Scholar
|
|
12
|
Wuensch T, Wizenty J, Quint J, Spitz W,
Bosma M, Becker O, Adler A, Veltzke-Schlieker W, Stockmann M, Weiss
S, et al: Expression analysis of fibronectin type III
domain-containing (FNDC) genes in inflammatory bowel disease and
colorectal cancer. Gastroenterol Res Pract. 2019:37841722019.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reddy RB, Khora SS and Suresh A: Molecular
prognosticators in clinically and pathologically distinct cohorts
of head and neck squamous cell carcinoma-A meta-analysis approach.
PLoS One. 14:e02189892019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhong M and Zhang Y, Yuan F, Peng Y, Wu J,
Yuan J, Zhu W and Zhang Y: High FNDC1 expression correlates with
poor prognosis in gastric cancer. Exp Ther Med. 16:3847–3854.
2018.PubMed/NCBI
|
|
15
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Clark AG and Vignjevic DM: Modes of cancer
cell invasion and the role of the microenvironment. Curr Opin Cell
Biol. 36:13–22. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eble JA and Niland S: The extracellular
matrix in tumor progression and metastasis. Clin Exp Metastasis.
36:171–198. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hao S, Lv J, Yang Q, Wang A, Li Z, Guo Y
and Zhang G: Identification of key genes and circular RNAs in human
gastric cancer. Med Sci Monit. 25:2488–2504. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen Z, Tao Q, Qiao B and Zhang L:
Silencing of LINC01116 suppresses the development of oral squamous
cell carcinoma by up-regulating microRNA-136 to inhibit FN1. Cancer
Manag Res. 11:6043–6059. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liang H, Yu M, Yang R, Zhang L, Zhang L,
Zhu D, Luo H, Hong Y, Yu T, Sun J, et al: A PTAL-miR-101-FN1 axis
promotes EMT and invasion-metastasis in serous ovarian cancer. Mol
Ther Oncolytics. 16:53–62. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ren J, Niu G, Wang X, Song T, Hu Z and Ke
C: Overexpression of FNDC1 in gastric cancer and its prognostic
significance. J Cancer. 9:4586–4595. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Klein T and Bischoff R: Physiology and
pathophysiology of matrix metalloproteases. Amino Acids.
41:271–290. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nemeth JA, Yousif R, Herzog M, Che M,
Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R and Cher
ML: Matrix metalloproteinase activity, bone matrix turnover, and
tumor cell proliferation in prostate cancer bone metastasis. J Natl
Cancer Inst. 94:17–25. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang H: Matrix metalloproteinase-9
(MMP-9) as a cancer biomarker and MMP-9 biosensors: Recent
advances. Sensors (Basel). 18:32492018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kotiyal S and Bhattacharya S: Breast
cancer stem cells, EMT and therapeutic targets. Biochem Biophys Res
Commun. 453:112–116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vincent CT and Fuxe J: EMT, inflammation
and metastasis. Semin Cancer Biol. 47:168–169. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Aoki M and Fujishita T: Oncogenic roles of
the PI3K/AKT/mTOR axis. Curr Top Microbiol Immunol. 407:153–189.
2017.PubMed/NCBI
|
|
28
|
Sharma VR, Gupta GK and Sharma AK, Batra
N, Sharma DK, Joshi A and Sharma AK: PI3K/Akt/mTOR intracellular
pathway and breast cancer: Factors, mechanism and regulation. Curr
Pharm Des. 23:1633–1638. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guerrero-Zotano A, Mayer IA and Arteaga
CL: PI3K/AKT/mTOR: Role in breast cancer progression, drug
resistance, and treatment. Cancer Metastasis Rev. 35:515–524. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xiao Y, Wei R, Yuan Z, Lan X, Kuang J, Hu
D, Song Y and Luo J: Rutin suppresses FNDC1 expression in bone
marrow mesenchymal stem cells to inhibit postmenopausal
osteoporosis. Am J Transl Res. 11:6680–6690. 2019.PubMed/NCBI
|
